Intravenous treatment with Mitoxantrone in active secondary progressive multiple sclerosis: effects on adaptive immune system.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON26011

Enrollment

Registered

2010-03-19

Start date

2010-03-22

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Secondary progressive multiple sclerosis

Interventions

Patients are treated acoording to normal neurological practice with mitoxantrone. During the planned blood controls 2 extra tubes will be taken.

Eligibility

Inclusion criteria

Inclusion criteria: 1. Secondary progressive MS patients who are treated with mitoxantrone according to normal neurological practice; 2. Age 18-65; 3. Relapse free for 30 days; 4. Willing to give informed consent.

Exclusion criteria

Exclusion criteria: 1. Relapsing remitting multiple sclerosis; 2. Treatment with intravenous corticosteroids in the last 30 days; 3. Any prior use of cyclophophamide, cladribine, anthracenediones or recieved a total lymphoid irradiation or mediastinal radiotherpay; 4. Use of experimental drugs 1 year prior to screening.

Design outcomes

Primary

Measure	Time frame
1. T cell compartment; 2. B-cell compartment; 3. Vitamin D.	—

Secondary

Measure	Time frame
Expanded disability status scale score.	—

Contacts

Public ContactS. Knippenberg

Postbus 616, Room 5.304

S.Knippenberg@NP.unimaas.nl+31 (0)43 3881432

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)